Crescent Biopharma (CBIO) Research & Development (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Research & Development of $19.4 million for Q2 2026, up 60.51% year-over-year from $12.1 million in Q2 2025, and up 8.31% quarter-over-quarter from $17.9 million in Q1 2026.
Crescent Biopharma (CBIO) Research & Development (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Research & Development for 14 consecutive years, with $19.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 60.51% year-over-year to $19.4 million; the TTM figure through Jun 2026 stood at $135.8 million (up 436.26% YoY), while the FY2025 annual figure was $138.1 million, up 868.36% from the prior year.
- Research & Development grew to $19.4 million in Q2 2026 per CBIO's latest filing, from $17.9 million in the prior quarter.
- Across five years, Research & Development topped out at $78.2 million in Q4 2025 and bottomed at $150000.0 in Q4 2024.
- Historically, Research & Development has averaged $12.3 million across 5 years, with a median of $6.2 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development plunged 97.16% — and 2025, when it soared 52033.33%.
- Crescent Biopharma's Research & Development stood at $5.9 million in 2022, then declined by 10.23% to $5.3 million in 2023, then slumped by 97.16% to $150000.0 in 2024, then jumped by 52033.33% to $78.2 million in 2025, then plunged by 75.2% to $19.4 million in 2026.
- Business Quant data shows CBIO's Research & Development at $19.4 million in Q2 2026, $17.9 million in Q1 2026, and $78.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 19.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.39 Mn |
| Mar 31, 2026 | 17.90 Mn |
| Dec 31, 2025 | 78.20 Mn |
| Sep 30, 2025 | 20.35 Mn |
| Jun 30, 2025 | 12.08 Mn |
| Mar 31, 2025 | 10.63 Mn |
| Dec 31, 2024 | 150,000.00 |
| Sep 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 5.29 Mn |
| Sep 30, 2023 | 5.29 Mn |
| Jun 30, 2023 | 4.07 Mn |
| Mar 31, 2023 | 5.42 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | 4.92 Mn |
| Jun 30, 2022 | 7.97 Mn |
| Mar 31, 2022 | 9.60 Mn |
| Dec 31, 2021 | 12.90 Mn |
| Sep 30, 2021 | 13.28 Mn |